To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ACR: Leflunomide Significantly Enhances Treatment Outcomes In Rheumatoid Arthritis URL: http://www.pslgroup.com/dg/1E886E.htm Doctor's Guide October 30, 2000
PHILADELPHIA, PA -- October 30, 2000 -- A landmark study highlighted during a press conference at the 64th Annual American College of Rheumatology (ACR) Annual Meeting in Philadelphia showed that twice as many patients taking leflunomide experienced significant benefit from the rheumatoid arthritis (RA) therapy, compared to the control group. These results are of particular importance because patients in this study were not responding to a traditional treatment, methotrexate; yet received significant therapeutic benefit when leflunomide, marketed under the tradename Arava™, was added. "The addition of leflunomide demonstrated significant therapeutic benefit for patients unresponsive to the standard RA therapy of methotrexate alone," commented Joel M. Kremer, current director of research at the Center for Rheumatology in Albany, New York and former head of the Division of Rheumatology at Albany Medical College. "This finding provides crucial insight into how we as rheumatologists should be approaching the treatment of rheumatoid arthritis, and should provide clinicians with evidence to re-evaluate their standard treatment protocol for RA." When introduced in 1998, leflunomide, an oral disease-modifying antirheumatic drug (DMARD), was the first new treatment for RA in more than a decade. It has been shown to retard structural damage and reduce signs and symptoms in all stages and severities of RA. RA -- one of the most common forms of arthritis -- is a potentially crippling autoimmune disease that affects more than two million Americans, 70 percent of whom are women. In a 24-week multicenter, randomized, placebo-controlled trial, 263 patients with active RA who were failing on methotrexate alone, were randomized to receive 10 mg/day of leflunomide with methotrexate (n=130; mean dose = 16.7 mg/wk) or placebo with methotrexate (n=133; mean dose = 16.2 mg/week). Dose adjustments were made based on tolerability and efficacy. The primary efficacy endpoint was the ACR 20 response rate assessed at 24 weeks. ACR criteria for response include the following: 1) at least a 20 percent improvement in both tender and swollen joint count, and 2) at least a 20 percent improvement in three of the following five criteria: patient's assessment of disease activity; investigator's assessment of disease activity; pain intensity; functional/disability measure; and acute phase reactants. More than twice as many patients in the leflunomide group (46 percent) were responders compared to the control group (20 percent), demonstrating a clear and significant therapeutic advantage for patients in the leflunomide group. The combination therapy was well tolerated; adverse events observed were minor and included diarrhea, nausea and dizziness. "We are excited to present data that proves the significant benefit of Arava when added to a traditional therapy like methotrexate," said Dr. Kremer. "I encourage physicians to evaluate this treatment plan for their RA patients, to provide clinically significant additional therapeutic benefit." --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.